Rathbones Group PLC Sells 18,632 Shares of DexCom, Inc. $DXCM

Rathbones Group PLC cut its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 13.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 119,891 shares of the medical device company’s stock after selling 18,632 shares during the quarter. Rathbones Group PLC’s holdings in DexCom were worth $7,957,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the stock. Trust Co. of Vermont grew its stake in DexCom by 14.8% in the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock valued at $74,000 after purchasing an additional 145 shares in the last quarter. CVA Family Office LLC grew its stake in DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 147 shares in the last quarter. GAMMA Investing LLC grew its stake in DexCom by 2.5% in the third quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock valued at $474,000 after purchasing an additional 169 shares in the last quarter. IFP Advisors Inc grew its stake in DexCom by 24.7% in the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock valued at $61,000 after purchasing an additional 178 shares in the last quarter. Finally, Inspire Investing LLC grew its stake in DexCom by 6.1% in the third quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company’s stock valued at $211,000 after purchasing an additional 180 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

DXCM has been the subject of a number of analyst reports. Barclays restated an “underweight” rating and issued a $72.00 price target (up from $71.00) on shares of DexCom in a research note on Friday, February 13th. Citigroup raised their price target on DexCom from $77.00 to $84.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Canaccord Genuity Group set a $95.00 price target on DexCom and gave the company a “buy” rating in a research note on Friday, February 13th. Mizuho raised their price target on DexCom from $78.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday, February 13th. Finally, Truist Financial restated a “buy” rating and issued a $80.00 price target (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, DexCom has an average rating of “Moderate Buy” and a consensus price target of $86.50.

DexCom Stock Performance

DXCM opened at $63.21 on Tuesday. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The stock has a market cap of $24.33 billion, a price-to-earnings ratio of 30.10, a PEG ratio of 1.21 and a beta of 1.55. The business has a 50 day moving average of $68.91 and a 200-day moving average of $66.99. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.03. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The company had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same period last year, the firm posted $0.45 earnings per share. The business’s revenue was up 13.1% on a year-over-year basis. On average, equities research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity

In other news, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $64.85, for a total value of $110,245.00. Following the completion of the sale, the executive vice president directly owned 112,904 shares of the company’s stock, valued at $7,321,824.40. This trade represents a 1.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.32% of the stock is currently owned by insiders.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.